Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension

Intensive Care National Audit & Research Centre0 sites2,600 target enrollmentApril 11, 2017

Overview

2019 Protocol article in https://doi.org/10.1177/1751143719870088 (added 13/09/2019) 2020 Results article in https://www.ncbi.nlm.nih.gov/pubmed/32049269 (added 13/02/2020) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33648623/ (added 03/03/2021) 2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/34093727/ (added 03/05/2024)

Registry

who.int

Start Date

April 11, 2017

End Date

October 31, 2019

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

Intensive Care National Audit & Research Centre

•Current inclusion criteria as of 16/02/2018:
•1\. Age 65 years or older
•2\. Vasodilatory hypotension as assessed by treating clinician
•3\. Started infusion (for at least one hour) of vasopressors within prior 6 hours (if noradrenaline, then a minimum dose of 0\.1 µg kg\-1 min\-1\)
•4\. Adequate fluid resuscitation is completed or ongoing
•5\. Vasopressors expected to continue for 6 hours or more as assessed by treating clinician
•Previous inclusion criteria:
•1\. Age 65 years or older
•2\. Vasodilatory hypotension as assessed by treating clinician
•3\. Decision to start vasopressors or started within prior 6 hours following/during adequate fluid resuscitation

•1\. Vasopressors being used solely as therapy for bleeding, acute ventricular failure (left or right) or post\-cardiopulmonary bypass vasoplegia
•2\. Ongoing treatment for brain injury or spinal cord injury
•3\. Death perceived as imminent
•4\. Previous enrolment to the 65 Trial